Olaparib in ovarian cancer with BRCA mutation

被引：5
|
作者：
Pujade-Lauraine, Eric [1 ]
Combe, Pierre [2 ]
机构：
[1] GH Paris Ctr, Ctr Canc Femme & Rech Clin, F-75181 Paris 04, France
[2] Hop Europeen Georges Pompidou, Serv Oncol Med, F-75015 Paris, France
来源：
BULLETIN DU CANCER | 2015年 / 102卷 / 06期
关键词：
BRCA; Ovarian cancer; Olaparib; PARP;
D O I：
10.1016/S0007-4551(15)31221-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
With 4500 new cases and 3200 death each year, ovarian cancer is the first cause of mortality for gynecological cancer in France. Without any efficient screening, it is usually diagnosed around the age of 60 years at an advanced stage. The emergence of olaparib, a new targeted therapy, represents a major opportunity.
引用
收藏
页码：S82 / S84
页数：3
相关论文
共 50 条
  • [31] Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers
    Ramus, Susan J.
    Antoniou, Antonis C.
    Kuchenbaecker, Karoline B.
    Soucy, Penny
    Beesley, Jonathan
    Chen, Xiaoqing
    McGuffog, Lesley
    Sinilnikova, Olga M.
    Healey, Sue
    Barrowdale, Daniel
    Lee, Andrew
    Thomassen, Mads
    HUMAN MUTATION, 2012, 33 (04) : 690 - 702
  • [32] Real-world experience of olaparib maintenance in high grade serous recurrent ovarian cancer patients with BRCA 1/2 mutation
    Paik, E. S.
    Kim, J.
    Kim, T-J.
    Choi, C. H.
    Lee, J-W.
    Bae, D-S.
    Kim, B-G.
    ANNALS OF ONCOLOGY, 2018, 29 : 84 - 84
  • [33] PRECLINICAL STUDIES OF THE PARP INHIBITOR OLAPARIB IN COMBINATION WITH IMATINIB IN BRCA STRATIFIED OVARIAN CANCER
    Matheson, E.
    Salehan, M.
    Mukhopadhyay, A.
    Curtin, N. J.
    Drew, Y.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2016, 26 : 673 - 673
  • [34] Preclinical evaluation of olaparib and metformin combination in BRCA1 wildtype ovarian cancer
    Hijaz, M.
    Chhina, J.
    Mert, I.
    Taylor, M.
    Dar, S.
    Al-Wahab, Z.
    Ali-Fehmi, R.
    Buekers, T.
    Munkarah, A. R.
    Rattan, R.
    GYNECOLOGIC ONCOLOGY, 2016, 142 (02) : 323 - 331
  • [35] Olaparib Treatment in a Patient with Advanced Gallbladder Cancer Harboring BRCA1 Mutation
    Li, Xiaofen
    Gao, Limin
    Qiu, Meng
    Cao, Dan
    ONCOTARGETS AND THERAPY, 2021, 14 : 2815 - 2819
  • [36] Olaparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer and a BRCA1 and/or BRCA2 mutation: SOLO1 China cohort
    Wu, Lingying
    Zhu, Jianqing
    Yin, Rutie
    Wu, Xiaohua
    Lou, Ge
    Wang, Jing
    Gao, Yunong
    Kong, Beihua
    Lu, Xin
    Zhou, Qi
    Wang, Yueling
    Chen, Youguo
    Lu, Weiguo
    Li, Wei
    Cheng, Ying
    Liu, Jihong
    Ma, Xin
    Zhang, Jing
    GYNECOLOGIC ONCOLOGY, 2021, 160 (01) : 175 - 181
  • [37] Breast Cancer Surveillance Following Ovarian Cancer in BRCA Mutation Carriers
    Fong, Abigail
    Cass, Ilana
    John, Catherine
    Gillen, Jessica
    Moore, Kathleen M.
    Gangi, Alexandra
    Walsh, Christine
    Li, Andrew J.
    Rimel, Bobbie J.
    Karlan, Beth Y.
    Amersi, Farin
    AMERICAN SURGEON, 2020, 86 (10) : 1243 - 1247
  • [38] Cancer frequency in BRCA mutation families with hereditary breast and ovarian cancer
    Cajal, Teresa Ramon y
    Capdevila, Jaume
    Carrera, Gemma
    Villanueva, Rafael
    Puig, Teresa
    Gich, Ignasi
    Diez, Orland
    Alonso, M. Carmen
    Barnadas, Agusti
    ANNALS OF ONCOLOGY, 2006, 17 : 275 - 275
  • [39] Breast cancer surveillance following ovarian cancer in BRCA mutation carriers
    John, Catherine S.
    Fong, Abigail
    Alban, Rodrigo
    Gillen, Jessica
    Moore, Kathleen M.
    Walsh, Christine S.
    Li, Andrew J.
    Rimel, B. J.
    Amersi, Farin
    Cass, Ilana
    GYNECOLOGIC ONCOLOGY, 2022, 164 (01) : 202 - 207
  • [40] Breast cancer surveillance following ovarian cancer in BRCA mutation carriers
    Cass, I.
    John, C.
    Gillen, J.
    Moore, K. N.
    Walsh, C.
    Li, A. J.
    Rimel, B. J.
    Karlan, B. Y.
    Amersi, F.
    GYNECOLOGIC ONCOLOGY, 2019, 154 : 212 - 213
12345